Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Porton Alectinib Hydrochloride

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    Alectinib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Roche’s Alecensa receives NICE to treat ALK-positive lung cancer
    Roche’s Alecensa receives NICE to treat ALK-positive lung cancer

    22 Oct 2024

    // PMLIVE

    https://pmlive.com/pharma_news/roches-alecensa-receives-nice-recommendation-to-treat-alk-positive-lung-cancer/

    PMLIVE
    22 Oct 2024
    Share Share
    Chugai's Alecensa Approved In Japan For Early-Stage ALK+ NSCLC
    Chugai's Alecensa Approved In Japan For Early-Stage ALK+ NSCLC

    29 Aug 2024

    // PHARMABIZ

    https://www.pharmabiz.com/NewsDetails.aspx?aid=172159&sid=2

    PHARMABIZ
    29 Aug 2024
    Share Share
    Taiwan FDA Approves Chugai's Alecensa For Early Stage ALK+ NSCLC
    Taiwan FDA Approves Chugai's Alecensa For Early Stage ALK+ NSCLC

    03 Aug 2024

    // PHARMABIZ

    https://www.pharmabiz.com/NewsDetails.aspx?aid=171663&sid=2

    PHARMABIZ
    03 Aug 2024
    Share Share
    EU Approves Roche's Alecensa As Targeted Adjuvant For ALK+ Lung Cancer
    EU Approves Roche's Alecensa As Targeted Adjuvant For ALK+ Lung Cancer

    10 Jun 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/06/10/2895717/0/en/European-Commission-approves-Roche-s-Alecensa-as-the-first-and-only-targeted-adjuvant-treatment-for-people-with-ALK-positive-early-stage-lung-cancer.html

    GLOBENEWSWIRE
    10 Jun 2024
    Share Share
    FDA approves alectinib as adjuvant treatment for ALK-positive non-small cell lung cancer
    FDA approves alectinib as adjuvant treatment for ALK-positive non-small cell lung cancer

    19 Apr 2024

    // FDA

    https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-alectinib-adjuvant-treatment-alk-positive-non-small-cell-lung-cancer#:~:text=On%20April%2018%2C%202024%2C%20the,by%20an%20FDA%2Dapproved%20test.

    FDA
    19 Apr 2024
    Share Share
    FDA Approves Roche's Alecensa As First ALK+ Early Lung Cancer Drug
    FDA Approves Roche's Alecensa As First ALK+ Early Lung Cancer Drug

    19 Apr 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/04/19/2865931/0/en/FDA-approves-Roche-s-Alecensa-as-the-first-adjuvant-treatment-for-people-with-ALK-positive-early-stage-lung-cancer.html

    GLOBENEWSWIRE
    19 Apr 2024
    Share Share